Annual revenue:
$63.63B+$4.07B(+6.84%)Summary
- As of today (April 15, 2025), PFE annual revenue is $63.63 billion, with the most recent change of +$4.07 billion (+6.84%) on December 1, 2024.
- During the last 3 years, PFE annual revenue has fallen by -$17.66 billion (-21.73%).
- PFE annual revenue is now -37.11% below its all-time high of $101.17 billion, reached on December 31, 2022.
Performance
PFE Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly revenue:
$17.76B+$63.00M(+0.36%)Summary
- As of today (April 15, 2025), PFE quarterly revenue is $17.76 billion, with the most recent change of +$63.00 million (+0.36%) on December 1, 2024.
- Over the past year, PFE quarterly revenue has stayed the same.
- PFE quarterly revenue is now -35.97% below its all-time high of $27.74 billion, reached on June 1, 2022.
Performance
PFE Quarterly revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM revenue:
$63.63B+$3.19B(+5.29%)Summary
- As of today (April 15, 2025), PFE TTM revenue is $63.63 billion, with the most recent change of +$3.19 billion (+5.29%) on December 1, 2024.
- Over the past year, PFE TTM revenue has stayed the same.
- PFE TTM revenue is now -37.18% below its all-time high of $101.28 billion, reached on June 1, 2022.
Performance
PFE TTM revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
PFE Revenue Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +6.8% | 0.0% | 0.0% |
| 3 y3 years | -21.7% | 0.0% | 0.0% |
| 5 y5 years | +55.5% | +76.2% | +68.0% |
PFE Revenue Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -37.1% | +6.8% | -36.0% | +36.6% | -37.2% | +13.7% |
| 5 y | 5-year | -37.1% | +55.5% | -36.0% | +80.1% | -37.2% | +98.4% |
| alltime | all time | -37.1% | +1550.7% | -36.0% | +1831.3% | -37.2% | +6817.4% |
Pfizer Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $63.63B(+6.8%) | $17.76B(+0.4%) | $63.63B(+5.3%) |
| Sep 2024 | - | $17.70B(+33.3%) | $60.43B(+7.5%) |
| Jun 2024 | - | $13.28B(-10.7%) | $56.22B(+0.5%) |
| Mar 2024 | - | $14.88B(+2.1%) | $55.95B(-6.1%) |
| Dec 2023 | $59.55B(-41.1%) | $14.57B(+8.0%) | $59.55B(-15.1%) |
| Sep 2023 | - | $13.49B(+3.7%) | $70.12B(-11.5%) |
| Jun 2023 | - | $13.01B(-29.6%) | $79.26B(-15.7%) |
| Mar 2023 | - | $18.48B(-26.5%) | $94.00B(-7.1%) |
| Dec 2022 | $101.17B(+24.5%) | $25.14B(+11.0%) | $101.18B(+1.3%) |
| Sep 2022 | - | $22.64B(-18.4%) | $99.88B(-1.4%) |
| Jun 2022 | - | $27.74B(+8.1%) | $101.28B(+9.6%) |
| Mar 2022 | - | $25.66B(+7.6%) | $92.43B(+13.7%) |
| Dec 2021 | $81.29B(+95.2%) | $23.84B(-0.8%) | $81.29B(+18.0%) |
| Sep 2021 | - | $24.04B(+27.2%) | $68.88B(+25.0%) |
| Jun 2021 | - | $18.90B(+30.2%) | $55.12B(+19.6%) |
| Mar 2021 | - | $14.52B(+27.0%) | $46.08B(+10.6%) |
| Dec 2020 | $41.65B(+1.8%) | $11.43B(+11.2%) | $41.65B(+29.9%) |
| Sep 2020 | - | $10.28B(+4.2%) | $32.07B(-7.0%) |
| Jun 2020 | - | $9.86B(-2.2%) | $34.47B(-9.0%) |
| Mar 2020 | - | $10.08B(+447.1%) | $37.87B(-7.4%) |
| Dec 2019 | $40.91B(+0.2%) | $1.84B(-85.5%) | $40.91B(+1.7%) |
| Sep 2019 | - | $12.68B(-4.4%) | $40.22B(-1.5%) |
| Jun 2019 | - | $13.26B(+1.1%) | $40.84B(-0.5%) |
| Mar 2019 | - | $13.12B(+1035.8%) | $41.04B(+0.5%) |
| Dec 2018 | $40.83B(-22.3%) | $1.16B(-91.3%) | $40.83B(-23.5%) |
| Sep 2018 | - | $13.30B(-1.2%) | $53.37B(+0.2%) |
| Jun 2018 | - | $13.47B(+4.3%) | $53.24B(+1.1%) |
| Mar 2018 | - | $12.91B(-5.8%) | $52.67B(+0.2%) |
| Dec 2017 | $52.55B(-0.5%) | $13.70B(+4.1%) | $52.55B(+0.1%) |
| Sep 2017 | - | $13.17B(+2.1%) | $52.47B(+0.2%) |
| Jun 2017 | - | $12.90B(+0.9%) | $52.35B(-0.5%) |
| Mar 2017 | - | $12.78B(-6.2%) | $52.60B(-0.4%) |
| Dec 2016 | $52.82B(+8.1%) | $13.63B(+4.5%) | $52.83B(-0.8%) |
| Sep 2016 | - | $13.04B(-0.8%) | $53.24B(+1.8%) |
| Jun 2016 | - | $13.15B(+1.1%) | $52.29B(+2.5%) |
| Mar 2016 | - | $13.01B(-7.4%) | $50.99B(+4.4%) |
| Dec 2015 | $48.85B(-1.5%) | $14.05B(+16.2%) | $48.85B(+1.9%) |
| Sep 2015 | - | $12.09B(+2.0%) | $47.92B(-0.6%) |
| Jun 2015 | - | $11.85B(+9.1%) | $48.20B(-1.9%) |
| Mar 2015 | - | $10.86B(-17.2%) | $49.12B(-1.0%) |
| Dec 2014 | $49.60B(-3.8%) | $13.12B(+6.1%) | $49.60B(-0.9%) |
| Sep 2014 | - | $12.36B(-3.2%) | $50.05B(-0.6%) |
| Jun 2014 | - | $12.77B(+12.5%) | $50.33B(-0.4%) |
| Mar 2014 | - | $11.35B(-16.3%) | $50.53B(-2.0%) |
| Dec 2013 | $51.58B(-5.6%) | $13.56B(+7.2%) | $51.58B(-0.6%) |
| Sep 2013 | - | $12.64B(-2.5%) | $51.92B(-0.6%) |
| Jun 2013 | - | $12.97B(+4.5%) | $52.23B(-1.9%) |
| Mar 2013 | - | $12.41B(-10.7%) | $53.22B(-4.4%) |
| Dec 2012 | $54.66B(-10.4%) | $13.89B(+7.2%) | $55.70B(+3.7%) |
| Sep 2012 | - | $12.95B(-7.3%) | $53.72B(-6.4%) |
| Jun 2012 | - | $13.97B(-6.2%) | $57.38B(-4.2%) |
| Mar 2012 | - | $14.88B(+24.9%) | $59.90B(-2.6%) |
| Dec 2011 | $61.03B(-6.3%) | $11.92B(-28.2%) | $61.51B(-5.4%) |
| Sep 2011 | - | $16.61B(+0.8%) | $65.06B(+1.0%) |
| Jun 2011 | - | $16.48B(-0.1%) | $64.44B(-1.0%) |
| Mar 2011 | - | $16.50B(+6.7%) | $65.09B(-0.1%) |
| Dec 2010 | $65.17B(+30.3%) | $15.46B(-3.3%) | $65.17B(-1.6%) |
| Sep 2010 | - | $15.99B(-6.6%) | $66.24B(+7.1%) |
| Jun 2010 | - | $17.13B(+3.4%) | $61.87B(+11.0%) |
| Mar 2010 | - | $16.58B(+0.2%) | $55.72B(+11.4%) |
| Dec 2009 | $50.01B(+3.5%) | $16.54B(+42.3%) | $50.01B(+9.1%) |
| Sep 2009 | - | $11.62B(+5.8%) | $45.82B(-0.8%) |
| Jun 2009 | - | $10.98B(+1.1%) | $46.17B(-2.4%) |
| Mar 2009 | - | $10.87B(-12.0%) | $47.31B(-2.0%) |
| Dec 2008 | $48.30B(-0.3%) | $12.35B(+3.1%) | $48.30B(-1.1%) |
| Sep 2008 | - | $11.97B(-1.3%) | $48.82B(-0.0%) |
| Jun 2008 | - | $12.13B(+2.4%) | $48.84B(+2.2%) |
| Mar 2008 | - | $11.85B(-7.9%) | $47.79B(-1.3%) |
| Dec 2007 | $48.42B(+0.1%) | $12.87B(+7.3%) | $48.42B(+0.6%) |
| Sep 2007 | - | $11.99B(+8.2%) | $48.15B(-0.6%) |
| Jun 2007 | - | $11.08B(-11.1%) | $48.44B(-1.3%) |
| Mar 2007 | - | $12.47B(-1.0%) | $49.10B(+1.5%) |
| Dec 2006 | $48.37B(+2.0%) | $12.60B(+2.6%) | $48.37B(+0.1%) |
| Sep 2006 | - | $12.28B(+4.6%) | $48.31B(+2.2%) |
| Jun 2006 | - | $11.74B(-0.1%) | $47.30B(+0.6%) |
| Mar 2006 | - | $11.75B(-6.4%) | $47.01B(-2.8%) |
| Dec 2005 | $47.41B(-3.2%) | $12.55B(+11.4%) | $48.35B(+2.4%) |
| Sep 2005 | - | $11.26B(-1.7%) | $47.20B(-3.2%) |
| Jun 2005 | - | $11.45B(-12.5%) | $48.77B(-1.7%) |
| Mar 2005 | - | $13.09B(+14.9%) | $49.59B(+1.2%) |
| Dec 2004 | $48.99B | $11.39B(-11.2%) | $48.99B(-5.0%) |
| Sep 2004 | - | $12.83B(+4.5%) | $51.57B(+0.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2004 | - | $12.27B(-1.7%) | $51.09B(+4.9%) |
| Mar 2004 | - | $12.49B(-10.7%) | $48.72B(+8.9%) |
| Dec 2003 | $44.74B(+38.5%) | $13.98B(+13.2%) | $44.76B(+11.8%) |
| Sep 2003 | - | $12.35B(+24.7%) | $40.03B(+12.2%) |
| Jun 2003 | - | $9.90B(+16.1%) | $35.68B(+7.9%) |
| Mar 2003 | - | $8.53B(-7.9%) | $33.07B(+2.4%) |
| Dec 2002 | $32.29B(+11.3%) | $9.26B(+15.7%) | $32.29B(+11.2%) |
| Sep 2002 | - | $8.00B(+9.6%) | $29.03B(+0.6%) |
| Jun 2002 | - | $7.30B(-5.8%) | $28.86B(-1.3%) |
| Mar 2002 | - | $7.75B(+29.2%) | $29.25B(+0.3%) |
| Dec 2001 | $29.02B(-1.1%) | $6.00B(-23.4%) | $29.15B(-6.6%) |
| Sep 2001 | - | $7.82B(+1.8%) | $31.20B(+2.2%) |
| Jun 2001 | - | $7.69B(+0.5%) | $30.54B(+2.3%) |
| Mar 2001 | - | $7.64B(-5.0%) | $29.84B(+1.6%) |
| Dec 2000 | $29.36B(+7.2%) | $8.05B(+12.4%) | $29.36B(+1.8%) |
| Sep 2000 | - | $7.16B(+2.4%) | $28.84B(+1.4%) |
| Jun 2000 | - | $6.99B(-2.4%) | $28.43B(+1.7%) |
| Mar 2000 | - | $7.16B(-5.0%) | $27.96B(+13.1%) |
| Dec 1999 | $27.38B(+17.8%) | $7.53B(+11.7%) | $24.72B(-19.6%) |
| Sep 1999 | - | $6.75B(+3.5%) | $30.74B(+12.5%) |
| Jun 1999 | - | $6.52B(+65.9%) | $27.33B(+13.3%) |
| Mar 1999 | - | $3.93B(-71.0%) | $24.12B(+3.8%) |
| Dec 1998 | $23.23B(+110.1%) | $13.55B(+307.0%) | $23.23B(+82.2%) |
| Sep 1998 | - | $3.33B(+0.5%) | $12.75B(+4.8%) |
| Jun 1998 | - | $3.31B(+9.1%) | $12.17B(+3.4%) |
| Mar 1998 | - | $3.04B(-1.2%) | $11.77B(+0.3%) |
| Dec 1997 | $11.05B(+12.1%) | $3.07B(+11.8%) | $11.73B(+13.0%) |
| Sep 1997 | - | $2.75B(-5.7%) | $10.38B(-0.5%) |
| Jun 1997 | - | $2.91B(-3.0%) | $10.44B(+2.5%) |
| Mar 1997 | - | $3.00B(+74.7%) | $10.18B(+3.2%) |
| Dec 1996 | $9.86B(-1.6%) | $1.72B(-38.7%) | $9.86B(-9.4%) |
| Sep 1996 | - | $2.80B(+5.3%) | $10.89B(+2.5%) |
| Jun 1996 | - | $2.66B(-0.8%) | $10.63B(+1.7%) |
| Mar 1996 | - | $2.68B(-2.3%) | $10.45B(+2.7%) |
| Dec 1995 | $10.02B(+21.0%) | $2.74B(+8.1%) | $10.17B(+4.6%) |
| Sep 1995 | - | $2.54B(+2.3%) | $9.72B(+5.0%) |
| Jun 1995 | - | $2.48B(+3.3%) | $9.26B(+6.4%) |
| Mar 1995 | - | $2.40B(+4.5%) | $8.70B(+5.1%) |
| Dec 1994 | $8.28B(+10.7%) | $2.30B(+10.9%) | $8.28B(+3.9%) |
| Sep 1994 | - | $2.07B(+7.9%) | $7.97B(+2.6%) |
| Jun 1994 | - | $1.92B(-3.0%) | $7.77B(+2.3%) |
| Mar 1994 | - | $1.98B(-0.3%) | $7.59B(+1.5%) |
| Dec 1993 | $7.48B(+3.4%) | $1.99B(+6.2%) | $7.48B(+0.6%) |
| Sep 1993 | - | $1.87B(+7.1%) | $7.44B(+0.6%) |
| Jun 1993 | - | $1.75B(-6.4%) | $7.39B(+0.7%) |
| Mar 1993 | - | $1.87B(-4.1%) | $7.34B(+1.5%) |
| Dec 1992 | $7.23B(+4.0%) | $1.95B(+6.5%) | $7.23B(+1.4%) |
| Sep 1992 | - | $1.83B(+7.9%) | $7.13B(+0.8%) |
| Jun 1992 | - | $1.69B(-3.8%) | $7.08B(+0.9%) |
| Mar 1992 | - | $1.76B(-4.8%) | $7.02B(+0.9%) |
| Dec 1991 | $6.95B(+8.5%) | $1.85B(+4.4%) | $6.95B(+0.9%) |
| Sep 1991 | - | $1.77B(+8.7%) | $6.89B(+1.9%) |
| Jun 1991 | - | $1.63B(-3.8%) | $6.76B(+2.0%) |
| Mar 1991 | - | $1.70B(-5.0%) | $6.62B(+3.3%) |
| Dec 1990 | $6.41B(+13.0%) | $1.79B(+8.7%) | $6.41B(+4.8%) |
| Sep 1990 | - | $1.64B(+9.8%) | $6.11B(+3.5%) |
| Jun 1990 | - | $1.50B(+0.9%) | $5.91B(+3.4%) |
| Mar 1990 | - | $1.48B(-0.8%) | $5.72B(+0.8%) |
| Dec 1989 | $5.67B(+5.3%) | $1.49B(+3.9%) | $5.67B(+2.3%) |
| Sep 1989 | - | $1.44B(+10.4%) | $5.55B(+1.0%) |
| Jun 1989 | - | $1.30B(-9.3%) | $5.49B(-0.6%) |
| Mar 1989 | - | $1.44B(+5.0%) | $5.52B(+2.6%) |
| Dec 1988 | $5.39B(+9.5%) | $1.37B(-1.1%) | $5.39B(+1.8%) |
| Sep 1988 | - | $1.38B(+3.5%) | $5.29B(+1.6%) |
| Jun 1988 | - | $1.34B(+3.0%) | $5.21B(+2.1%) |
| Mar 1988 | - | $1.30B(+1.8%) | $5.10B(+3.6%) |
| Dec 1987 | $4.92B(+9.9%) | $1.28B(-1.7%) | $4.92B(+2.3%) |
| Sep 1987 | - | $1.30B(+5.8%) | $4.81B(+2.9%) |
| Jun 1987 | - | $1.23B(+9.6%) | $4.67B(+2.4%) |
| Mar 1987 | - | $1.12B(-3.7%) | $4.56B(+2.0%) |
| Dec 1986 | $4.48B(+11.2%) | $1.16B(-0.0%) | $4.48B(+2.4%) |
| Sep 1986 | - | $1.16B(+4.0%) | $4.37B(+3.6%) |
| Jun 1986 | - | $1.12B(+8.3%) | $4.22B(+2.8%) |
| Mar 1986 | - | $1.03B(-2.4%) | $4.10B(+2.2%) |
| Dec 1985 | $4.02B(+4.4%) | $1.06B(+4.5%) | $4.02B(+2.3%) |
| Sep 1985 | - | $1.01B(+1.1%) | $3.93B(+0.8%) |
| Jun 1985 | - | $1.00B(+5.9%) | $3.90B(+0.4%) |
| Mar 1985 | - | $945.70M(-2.1%) | $3.88B(+0.7%) |
| Dec 1984 | $3.85B | $966.30M(-1.7%) | $3.85B(+33.5%) |
| Sep 1984 | - | $982.70M(-0.3%) | $2.89B(+51.6%) |
| Jun 1984 | - | $985.70M(+7.2%) | $1.91B(+107.2%) |
| Mar 1984 | - | $919.80M | $919.80M |
FAQ
- What is Pfizer annual revenue?
- What is the all time high annual revenue for Pfizer?
- What is Pfizer annual revenue year-on-year change?
- What is Pfizer quarterly revenue?
- What is the all time high quarterly revenue for Pfizer?
- What is Pfizer quarterly revenue year-on-year change?
- What is Pfizer TTM revenue?
- What is the all time high TTM revenue for Pfizer?
- What is Pfizer TTM revenue year-on-year change?
What is Pfizer annual revenue?
The current annual revenue of PFE is $63.63B
What is the all time high annual revenue for Pfizer?
Pfizer all-time high annual revenue is $101.17B
What is Pfizer annual revenue year-on-year change?
Over the past year, PFE annual revenue has changed by +$4.07B (+6.84%)
What is Pfizer quarterly revenue?
The current quarterly revenue of PFE is $17.76B
What is the all time high quarterly revenue for Pfizer?
Pfizer all-time high quarterly revenue is $27.74B
What is Pfizer quarterly revenue year-on-year change?
Over the past year, PFE quarterly revenue has changed by $0.00 (0.00%)
What is Pfizer TTM revenue?
The current TTM revenue of PFE is $63.63B
What is the all time high TTM revenue for Pfizer?
Pfizer all-time high TTM revenue is $101.28B
What is Pfizer TTM revenue year-on-year change?
Over the past year, PFE TTM revenue has changed by $0.00 (0.00%)